UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 115

Sortiert nach

DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy

Developmental cell, 2012-01, Vol.22 (1), p.38-51

2012

Link zum Volltext

Verfügbarkeit prüfen

Genome-wide transcription factor binding: beyond direct target regulation

Trends in genetics, 2011-04, Vol.27 (4), p.141-148

2011

Link zum Volltext

Verfügbarkeit prüfen

Skeletal muscle programming and re-programming

Current opinion in genetics & development, 2013-10, Vol.23 (5), p.568-573

2013

Link zum Volltext

Verfügbarkeit prüfen

Genetic and Epigenetic Determinants of Neurogenesis and Myogenesis

Developmental cell, 2012-04, Vol.22 (4), p.721-735

2012

Link zum Volltext

Verfügbarkeit prüfen

Conversion of MyoD to a Neurogenic Factor: Binding Site Specificity Determines Lineage

Cell reports (Cambridge), 2015-03, Vol.10 (12), p.1937-1946

2015

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Genome-Wide Binding of MyoD in Normal Human Myogenic Cells and Rhabdomyosarcomas Identifies Regional and Local Suppression of Promyogenic Transcription Factors

Molecular and Cellular Biology, 2013-02, Vol.33 (4), p.773-784

2013

Link zum Volltext

Verfügbarkeit prüfen

Discriminative motif analysis of high-throughput dataset

Bioinformatics, 2014-03, Vol.30 (6), p.775-783

2014

Link zum Volltext

Verfügbarkeit prüfen

Comparison of endogenous and overexpressed MyoD shows enhanced binding of physiologically bound sites

Skeletal muscle, 2013-04, Vol.3 (1), p.8-8, Article 8

2013

Link zum Volltext

Verfügbarkeit prüfen

Polycomb-mediated repression during terminal differentiation: what don't you want to be when you grow up?

Genes & development, 2011-05, Vol.25 (10), p.997-1003

2011

Link zum Volltext

Verfügbarkeit prüfen

Genome-wide binding of the basic helix-loop-helix myogenic inhibitor musculin has substantial overlap with MyoD: implications for buffering activity

Skeletal muscle, 2013-11, Vol.3 (1), p.26-26, Article 26

2013

Link zum Volltext

Verfügbarkeit prüfen

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Blood, 2016-09, Vol.128 (12), p.1562-1566

2016

Link zum Volltext

Verfügbarkeit prüfen

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study

Lung cancer (Amsterdam, Netherlands), 2020-07, Vol.145, p.126-131

2020

Link zum Volltext

Verfügbarkeit prüfen

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Blood, 2022-11, Vol.140 (Supplement 1), p.9046-9047

2022

Link zum Volltext

Verfügbarkeit prüfen

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Blood, 2017-12, Vol.130 (26), p.2829-2837

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT124: First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT124-CT124

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT167: First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT167-CT167

2020

Link zum Volltext

Verfügbarkeit prüfen

Induction of p100 Processing by NF-κB-inducing Kinase Involves Docking IκB Kinase α (IKKα) to p100 and IKKα-mediated Phosphorylation

The Journal of biological chemistry, 2004-07, Vol.279 (29), p.30099-30105

2004

Link zum Volltext

Verfügbarkeit prüfen

ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies

Blood, 2020-11, Vol.136 (Supplement 1), p.15-16

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-14-01-OT1-14-01

2022

Link zum Volltext

Verfügbarkeit prüfen

Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study

Gynecologic oncology, 2020-09, Vol.158 (3), p.640-645

2020

Link zum Volltext

Verfügbarkeit prüfen

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Blood, 2021-11, Vol.138 (Supplement 1), p.2601-2601

2021

Link zum Volltext

Verfügbarkeit prüfen

Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway

Science (American Association for the Advancement of Science), 2001-08, Vol.293 (5534), p.1495-1499

2001

Link zum Volltext

Verfügbarkeit prüfen

Genetic Evidence for the Essential Role of β-Transducin Repeat-containing Protein in the Inducible Processing of NF-κB2/p100

The Journal of biological chemistry, 2002-06, Vol.277 (25), p.22111-22114

2002

Link zum Volltext

Verfügbarkeit prüfen

Retroviral oncoprotein Tax induces processing of NF-κB2/p100 in T cells: evidence for the involvement of IKKα

The EMBO journal, 2001-12, Vol.20 (23), p.6805-6815

2001

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Blood, 2015-12, Vol.126 (23), p.587-587

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Englisch
(115)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Life Sciences & Biomedicine
(46)
Humans
(38)
Animals
(16)
Female
(15)
Male
(15)
Physical Sciences
(12)
Adult
(11)
Cell Biology
(11)
Technology
(11)
Mice
(10)
Science & Technology - Other Topics
(10)
Biochemistry & Molecular Biology
(9)
Middle Aged
(8)
Multidisciplinary Sciences
(8)
Adolescent
(6)
Biological And Medical Sciences
(6)
Computer Science
(6)
Physics
(6)
Risk Factors
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy

Genome-wide transcription factor binding: beyond direct target regulation

Skeletal muscle programming and re-programming

Genetic and Epigenetic Determinants of Neurogenesis and Myogenesis

Conversion of MyoD to a Neurogenic Factor: Binding Site Specificity Determines Lineage

Comparison of Genome-Wide Binding of MyoD in Normal Human Myogenic Cells and Rhabdomyosarcomas Identifies Regional and Local Suppression of Promyogenic Transcription Factors

Discriminative motif analysis of high-throughput dataset

Comparison of endogenous and overexpressed MyoD shows enhanced binding of physiologically bound sites

Polycomb-mediated repression during terminal differentiation: what don't you want to be when you grow up?

Genome-wide binding of the basic helix-loop-helix myogenic inhibitor musculin has substantial overlap with MyoD: implications for buffering activity

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL

Abstract CT124: First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers

Abstract CT167: First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer

Induction of p100 Processing by NF-κB-inducing Kinase Involves Docking IκB Kinase α (IKKα) to p100 and IKKα-mediated Phosphorylation

ALX148 Enhances the Depth and Durability of Response to Multiple AML Therapies

Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204)

Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Activation by IKKα of a Second, Evolutionary Conserved, NF-κB Signaling Pathway

Genetic Evidence for the Essential Role of β-Transducin Repeat-containing Protein in the Inducible Processing of NF-κB2/p100

Retroviral oncoprotein Tax induces processing of NF-κB2/p100 in T cells: evidence for the involvement of IKKα

Brentuximab Vedotin in Combination with Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study

Suchergebnisse filtern